Abstract
The pharmaceutical industry is developing fast in China and the market is getting more mature in recent years, which draws the attention of multinational producers and investors. Patent protection is important for the commercialization of pharmaceuticals in China. This article will introduce the prosecution and enforcement of pharmaceuticals in China, in view of the amendments to the Chinese Patent Law, particularly the upcoming fourth amendments to the Patent Law. Particular issues in connection with the prosecution of pharmaceuticals will focus on patentable subject matter, sufficient disclosure, medical use claims. Further, specific issues in relation to patent term, patent linkage, regulatory exclusivity and Bolar exemption will also be highlighted. Current problems and perspectives of the authors will be addressed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
